1. GlaxoSmithKline’s HIV drug Tivicay combined with Johnson & Johnson’s Edurant suppressed the virus and supports the company’s claim that a two-drug cocktail may be as effective as three-drug cocktail. ViiV Healthcare CEO Dominique Limet said the drugmaker will submit the dual-drug regimen to regulators in 2017. (WSJ)

2. Dexcom, which develops glucose monitoring systems, said the FDA approved its continuous glucose monitoring system, which can determine insulin doses without finger pricking. Patients perform finger-stick blood testing twice a day for calibration, and they can calculate their insulin dose thereafter from values displayed on the device’s receiver or smartphone app. (Medscape)

3. Walgreens Boots Alliance and Rite Aid plan to divest 865 Rite Aid stores to Fred’s Pharmacy for $950 million in cash in response to antitrust concerns by the Federal Trade Commission. The concerns stem from Walgreen’s proposed acquisition of Rite Aid, which was announced in 2015. (Forbes)

4. The FDA extended its review of Roche’s multiple-sclerosis drug Ocrevus until the end of March. Roche said the request for additional data is not related to safety or efficacy. (PMLive)

5. Biogen shareholders will receive one share of its hemophilia drug spinoff Bioverativ for every Biogen share they own, as part of the final step of it becoming an independent company. (Boston Globe)